Findings of transoesophageal echocardiogram in appropriately anticoagulated patients with persistent atrial fibrillation prior to planned cardioversion

被引:13
作者
Barysiene, Jurate [1 ,2 ]
Zebrauskaite, Aiste [1 ,2 ]
Petrikonyte, Dovile [1 ,2 ]
Marinskis, Germanas [1 ,2 ]
Aidietiene, Sigita [1 ,2 ]
Aidietis, Audrius [1 ,2 ]
机构
[1] Vilnius Univ Hosp, Santariskiu Clin, Ctr Cardiol & Angiol, 2 Santariskiu St, LT-08661 Vilnius, Lithuania
[2] Vilnius Univ, Clin Cardiovasc Dis, Fac Med, 21 Ciurlionio St, LT-03101 Vilnius, Lithuania
关键词
Atrial fibrillation; Non-vitamin K antagonist oral anticoagulants; Anticoagulation; Cardioversion; Transoesophageal echocardiogram; Thromboembolism; ORAL ANTICOAGULANTS; THERAPY; RISK; DABIGATRAN; MANAGEMENT; EFFICACY; THROMBUS; EVENTS; GUIDE;
D O I
10.1186/s12872-017-0503-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: To evaluate a diagnostic value of transoesophageal echocardiogram (TEE) in appropriately anticoagulated patients with a non-valvular atrial fibrillation (AF) and to establish possible additional indications for TEE; to evaluate the incidence of left atrial (LA) thrombi in appropriately anticoagulated patients in daily clinical practice. Methods: This retrospective study analyses data of 432 patients who had been anticoagulated by means of oral anticoagulants (OACs) prior to planned cardioversion during the period from 2012 to 2015. Thromboembolic (TE) and bleeding risks were assessed using CHA2DS2-VASc and HAS-BLED scores. Transthoracic and transoesophageal echocardiograms were evaluated. TE complications during 30 days after discharge were assessed. Results: 432 patients were selected, aged from 22 to 89 years (mean 65.0 +/- 11.5), 277 (64.1%) males and 155 (35.9%) females, 306 (70.8%) on warfarin and 126 (29.2%) on non-vitamin K antagonist oral anticoagulants (NOAC). Mean CHA2DS2-VASc score was 3.5 +/- 1.5. TEE was performed for 120 (27.8%) patients, more frequently for patients on NOACs and for ones with III degrees LA enlargement. TEE revealed LA thrombi in seven (5.8%) of the patients. In warfarin and NOACs groups thrombi were revealed in five (7.0%) and two (4.1%) patients, respectively. TEE did not reveal any thrombi in patients with normal left ventricular (LV) function; however, thrombi were found in two (6.1%) patients with slightly decreased LV function, and in five (17.9%) patients with markedly decreased LV function. In patients with decreased left ventricular ejection fraction (LVEF) thrombi in LA were found more frequently than in patients with normal and slightly decreased LVEF (17.9% vs 2.2%, p=0.008). CHA2DS2-VASc score of all 7 patients was >= 5. None of the patients after cardioversion had TE complications 30 days after discharge. Conclusions: The risk of LA thrombi in patients prepared for scheduled cardioversion in line with the guidelines is low. Higher risk of thrombi was present in patients with decreased LVEF (<= 40%), CHA2DS2-VASc >= 5. In order to assess more accurately indications to perform TEE for appropriately anticoagulated patients prior to scheduled cardioversion a study with larger number of patients is required.
引用
收藏
页数:8
相关论文
共 22 条
[1]   Effect of Weight Reduction and Cardiometabolic Risk Factor Management on Symptom Burden and Severity in Patients With Atrial Fibrillation A Randomized Clinical Trial [J].
Abed, Hany S. ;
Wittert, Gary A. ;
Leong, Darryl P. ;
Shirazi, Masoumeh G. ;
Bahrami, Bobak ;
Middeldorp, Melissa E. ;
Lorimer, Michelle F. ;
Lau, Dennis H. ;
Antic, Nicholas A. ;
Brooks, Anthony G. ;
Abhayaratna, Walter P. ;
Kalman, Jonathan M. ;
Sanders, Prashanthan .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (19) :2050-2060
[2]   ROLE OF PROPHYLACTIC ANTICOAGULATION FOR DIRECT-CURRENT CARDIOVERSION IN PATIENTS WITH ATRIAL-FIBRILLATION OR ATRIAL-FLUTTER [J].
ARNOLD, AZ ;
MICK, MJ ;
MAZUREK, RP ;
LOOP, FD ;
TROHMAN, RG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 19 (04) :851-855
[3]   EFFICACY OF ANTICOAGULANT THERAPY IN PREVENTING EMBOLISM RELATED TO DC ELECTRICAL CONVERSION OF ATRIAL FIBRILLATION [J].
BJERKELUND, CJ ;
ORNING, OM .
AMERICAN JOURNAL OF CARDIOLOGY, 1969, 23 (02) :208-+
[4]   . Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation [J].
Bushoven, Philipp ;
Linzbach, Sven ;
Vamos, Mate ;
Hohnloser, Stefan H. .
ARRHYTHMIA & ELECTROPHYSIOLOGY REVIEW, 2015, 4 (01) :44-46
[5]   CARDIOVERSION OF NONRHEUMATIC ATRIAL-FIBRILLATION - REDUCED THROMBOEMBOLIC COMPLICATIONS WITH 4 WEEKS OF PRECARDIOVERSION ANTICOAGULATION ARE RELATED TO ATRIAL THROMBUS RESOLUTION [J].
COLLINS, LJ ;
SILVERMAN, DI ;
DOUGLAS, PS ;
MANNING, WJ .
CIRCULATION, 1995, 92 (02) :160-163
[6]   Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: Evidence for gender differences in the studies of left ventricular dysfunction trials [J].
Dries, DL ;
Rosenberg, YD ;
Waclawiw, MA ;
Domanski, MJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (05) :1074-1080
[7]   Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation [J].
Flaker, Greg ;
Lopes, Renato D. ;
Al-Khatib, Sana M. ;
Hermosillo, Antonio G. ;
Hohnloser, Stefan H. ;
Tinga, Brian ;
Zhu, Jun ;
Mohan, Puneet ;
Garcia, David ;
Bartunek, Jozef ;
Vinereanu, Dragos ;
Husted, Steen ;
Harjola, Veli Pekka ;
Rosenqvist, Marten ;
Alexander, John H. ;
Granger, Christopher B. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (11) :1082-1087
[8]   Left atrial thrombus and prognosis after anticoagulation therapy in patients with atrial fibrillation [J].
Fukuda, Shota ;
Watanabe, Hiroyuki ;
Shimada, Kenei ;
Aikawa, Masaru ;
Kono, Yasushi ;
Jissho, Satoshi ;
Taguchi, Haruyuki ;
Umemura, Jun ;
Yoshiyama, Minoru ;
Shiota, Takahiro ;
Sumiyoshi, Tetsuya ;
Yoshikawa, Junichi .
JOURNAL OF CARDIOLOGY, 2011, 58 (03) :266-277
[9]   Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation [J].
Heidbuchel, Hein ;
Verhamme, Peter ;
Alings, Marco ;
Antz, Matthias ;
Diener, Hans-Christoph ;
Hacke, Werner ;
Oldgren, Jonas ;
Sinnaeve, Peter ;
Camm, A. John ;
Kirchhof, Paulus .
EUROPACE, 2015, 17 (10) :1467-1507
[10]   Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism? [J].
Johansson, Anna-Karin ;
Juhlin, Tord ;
Engdahl, Johan ;
Lind, Stefan ;
Hagwall, Kristina ;
Rorsman, Cecilia ;
Fodor, Emoke ;
Alenholt, Anna ;
Nordin, Astrid Paul ;
Rosenqvist, Marten ;
Frick, Mats .
EUROPACE, 2015, 17 (10) :1514-1517